# An Efficacy and Safety Study of Trabectedin Versus Doxorubicin-Based Chemotherapy in Participants With Translocation-Related Sarcomas (TRS)

> **NCT00796120** · PHASE3 · COMPLETED · sponsor: **Johnson & Johnson Pharmaceutical Research & Development, L.L.C.** · enrollment: 121 (actual)

## Conditions studied

- Sarcoma

## Interventions

- **DRUG:** Trabectedin
- **DRUG:** Doxorubicin
- **DRUG:** Ifosfamide

## Key facts

- **NCT ID:** NCT00796120
- **Lead sponsor:** Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-11
- **Primary completion:** 2012-08
- **Final completion:** 2014-08
- **Target enrollment:** 121 (ACTUAL)
- **Last updated:** 2015-12-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00796120

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00796120, "An Efficacy and Safety Study of Trabectedin Versus Doxorubicin-Based Chemotherapy in Participants With Translocation-Related Sarcomas (TRS)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00796120. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*